GE Answers Siemens' Challenge With Abbott Dx Buy, But Remains Quiet on Molecular Strategy | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
By inking a deal last week to acquire two of Abbott’s diagnostics businesses for $8.13 billion in cash, General Electric has taken a major step in its goal to reposition its Healthcare unit’s focus on an “early health model” that fuses in vitro and in vivo diagnostic technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.